Tarsus Pharma board chair Ackermann resigns; CEO Azamian succeeds; Yarno named lead independent director

Tarsus Pharmaceuticals, Inc.

Michael Ackermann resigned as Chairperson and Board member effective Dec 2, 2022; no disagreement with company.
Ackermann entered a 12-month consulting agreement, receiving 5,000 RSUs vesting in one year and continued equity vesting.
CEO Bobak Azamian appointed Board Chairperson effective Dec 2; will not receive additional compensation.
Wendy Yarno appointed Lead Independent Director effective Dec 2; granted 5,000 RSUs vesting in one year and $75,000 annual cash retainer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Ackermann

Chairperson of the Board

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2022-12-02
Successor: Bobak Azamian
Filed: December 7, 2022, 6:59 PM ET

Michael Ackermann, the Chairperson of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of his resignation as the Chairperson and as a member of the Board and any committees of the Board, effective December 2, 2022.

Role change

Wendy Yarno

Lead Independent Director

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2022-12-02
Filed: December 7, 2022, 6:59 PM ET

and Wendy Yarno, current member of the Board, as Lead Independent Director, each appointment effective as of December 2, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Ackermann resigned as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..

Action: resigned
Role: Chairperson of the Board

Exact text from the filing

Michael Ackermann, the Chairperson of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of his resignation as the Chairperson and as a member of the Board and any committees of the Board, effective December 2, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

and Wendy Yarno, current member of the Board, as Lead Independent Director, each appointment effective as of December 2, 2022.

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-22-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.